Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study

Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study

Levilimab (LVL) is a monoclonal antibody against the interleukin-6 receptor (IL6R). The article presents data obtained during 56 weeks of the AURORA phase II study.Objective: to evaluate the efficacy safety and immunogenicity of LVL in methotrexate (MTX) resistant patients with active rheumatoid art...

Full description

Bibliographic Details
Main Authors: V. I. Mazurov, E. G. Zotkin, I. Z. Gaydukova, E. P. Ilivanova, T. V. Kropotina, T. V. Plaksina, O. B. Nesmeyanova, N. F. Soroka, E. A. Kunder, E. A. Dokukina, Yu. N. Linkova, N. A. Kravtsova, P. S. Pukhtinskaya, A. V. Eremeeva, A. V. Zinkina-Orikhan, A. A. Lutckii
Format: Article
Language:Russian
Published: IMA PRESS LLC 2021-05-01
Series:Научно-практическая ревматология
Subjects:
levilimab
monoclonal anti-il-6 receptor antibody
rheumatoid arthritis
Online Access:https://rsp.mediar-press.net/rsp/article/view/3016

Internet

https://rsp.mediar-press.net/rsp/article/view/3016

Similar Items